Compare AbbVie Inc (ABBV) vs Badger Meter Inc (BMI) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Badger Meter (BMI) trades at $149.79, up 2.69% with a bullish technical signal from moving averages. The company maintains strong profitability with 14.56% net income margin and 19.6% ROE, though recent earnings misses and a securities class action lawsuit create headwinds. Valuation metrics show a P/E of 33.89 and P/S of 4.93, above industry averages.

While BMI demonstrates solid fundamentals and technical strength, the stock faces significant legal risks from multiple class action lawsuits alleging securities fraud. Analyst consensus is mixed with 28% buy ratings but a $144.80 price target below current levels. The combination of legal overhang and premium valuation creates a cautious near-term outlook despite strong operational performance.